Disability due to FAP progression Not measured · people with TTR‐FAP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Severity of peripheral neuropathy (expressed as the change in mNIS+7Ionis) Scale from: ‐22.3 (normal) to 346.3 (total impairment) · people with TTR‐FAP
1 finding from 1 review
QoL · people with TTR‐FAP
1 finding from 1 review
Has died · people with TTR‐FAP
Inotersen showed no clear difference in number of participants who died during the trial compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with TTR‐FAP
Inotersen may leads to higher number of dropouts due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of participants experiencing at least one severe adverse event · people with TTR‐FAP
Inotersen showed no clear difference in number of participants experiencing at least one severe adverse event compared with placebo (low certainty).
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
All‐cause mortality · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Proportion of participants with self‐rated clinically significant hair regrowth · women with FPHL
Minoxidil probably leads to higher the proportion of participants with self‐rated clinically… compared with placebo (moderate certainty).
1 finding from 1 review
Change in quality of life · women with FPHL
1 finding from 1 review
Adverse events · women with FPHL
Minoxidil showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Proportion of participants with investigator‐rated clinically significant hair regrowth · women with FPHL
Minoxidil probably leads to higher proportion of participants with investigator‐rated clinically… compared with placebo (moderate certainty).
1 finding from 1 review
Change from baseline to study conclusion in total hair count · women with FPHL
1 finding from 1 review
Degree of hair shedding from baseline to the end of the study · women with FPHL
1 finding from 1 review
Cosmetic appearance of the hair or participant satisfaction · women with FPHL
1 finding from 1 review
Change in quality (or pattern) of hair regrowth (e.g. thickness) · women with FPHL
1 finding from 1 review
Number of participants with any bleeding · People with a haematological disorder
1 finding from 1 review
Thromboembolism · People with a haematological disorder
1 finding from 1 review
Mortality (all‐cause) ‐ not reported · People with a haematological disorder
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · People with a haematological disorder
1 finding from 1 review